MEDINICE S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.85 PLN | -0.38% |
|
-3.68% | -19.90% |
| 03-28 | Medinice S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Medinice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2022 | 246K 60.96K 4.86M | Sales 2023 | 225K 55.75K 4.44M | Capitalization | 63.33M 15.69M 1.25B |
|---|---|---|---|---|---|
| Net income 2022 | -4M -991K -78.97M | Net income 2023 | -5M -1.24M -98.71M | EV / Sales 2022 | 272 x |
| Net cash position 2022 | 20.6M 5.11M 407M | Net cash position 2023 | 9.82M 2.43M 194M | EV / Sales 2023 | 238 x |
| P/E ratio 2022 |
-17.7
x | P/E ratio 2023 |
-12.4
x | Employees | 16 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.82% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.38% | ||
| 1 week | -3.68% | ||
| Current month | -19.07% | ||
| 1 month | -20.63% | ||
| 3 months | -20.71% | ||
| 6 months | -26.29% | ||
| Current year | -19.90% |
1 week
7.48
8.25
1 month
7.4810.00
Current year
7.4812.20
1 year
7.4818.05
3 years
7.4834.00
5 years
5.0041.30
10 years
4.9541.30
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | - | - | |
Sebastian Stec
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
Joanna Bogdanska
CHM | Chairman | - | - |
| Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 7.85 | -0.38% | 10,246 |
| 30/04/24 | 7.88 | +2.34% | 13,325 |
| 29/04/24 | 7.7 | -1.28% | 20,160 |
| 26/04/24 | 7.8 | -2.26% | 48,739 |
| 25/04/24 | 7.98 | -1.48% | 40,425 |
Delayed Quote Warsaw S.E., May 02, 2024 at 04:55 pm
More quotes
Medinice SA is a Poland-based company engaged in medical diagnostic and testing equipment business sector. The Company specializes in creating, developing and commercializing safe and minimally invasive solutions in the field of medicine, in particular cardiology and cardio surgery. Its portfolio comprises of projects, such as CathAIO, Cryoapplicator, Med-IConsole, Minimax, Pacepress and others. All of the Company's projects have a global potential. The Company cooperates with research centers in Poland and Europe. It strives to commercialize inventions brought by both co-founders of the Company and acquired projects through the sale of licenses worldwide in the production of medical devices.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.90% | 12.57M | |
| -15.52% | 18.54B | |
| +17.00% | 1.85B | |
| -0.51% | 1.66B | |
| +25.21% | 1.23B | |
| -13.90% | 989M | |
| -21.76% | 896M | |
| -5.01% | 744M | |
| -19.85% | 673M | |
| +7.31% | 490M |
- Stock Market
- Equities
- ICE Stock
